Alupent syrup: results of a six-month trial in asthmatic children.
A six-month clinical trial of Alupent Syrup was conducted in 23 school-age children with bronchial asthma to assess the long-term efficacy and safety of this dosage form of metaproterenol sulfate. At three intervals during the study period, double-bind crossover tests against placebo were performed. Pulmonary function measurements revealed significant improvement in PEFR and FEV, after metaproterenol, and the results obtained at the end of ths study demonstrated that no tolerance to the drug had developed. The absence of adverse reactions attested to the safety of the drug in long-term management of childhood asthma.
D000284:Administration, Oral; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001794:Blood Pressure; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008448:Maximal Expiratory Flow Rate; D009921:Metaproterenol / Q000008:administration & dosage* / Q000627:therapeutic use; D010919:Placebos; D011674:Pulse; D013147:Spirometry; D014797:Vital Capacity
D010919:Placebos; D009921:Metaproterenol